Citations

Clear

3030 citation(s) found for "Susan, M".

Summary: international consensus statement on nomenclature and classification of the congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and research purposes
Michelena, Héctor I. , Evangelista, Arturo , Maleszewski, Joseph J. , Edwards, William D. , Roman, Mary J. , Devereux, Richard B. , Fernández, Borja , Sierra-Galán, Lilia M. , Girdauskas, Evaldas , Delgado, Victoria , Lansac, Emmanuel , Bissell, Malenka M. , Hope, Michael D. , Sitges, Marta , Thourani, Vinod H. , Pibarot, Phillippe, Chandrasekaran, Krishnaswamy , Lancellotti, Patrizio , Forrest, John K. , Webb, John G. , Makkar, Raj , Leon, Martin B. , Markl, Michael , Ferrari, Victor A. , Roberts, William C. , Svensson, Lars G. , Braverman, Alan C. , Bavaria, Joseph E. , Sundt, Thoralf M. , Khoury, Gébrine El , Paulis, Ruggero De , Michelena, Hector I , Delgado, Victoria , Bissell, Malenka M , De Paulis, Ruggero , Enriquez-Sarano, Maurice , Markl, Michael , Ferrari, Victor A , Corte, Alessandro Della , Asch, Federico M. , Barker, Alex J. , De Kerchove, Laurent , Fernandes, Susan M , Fedak, Paul W M , Abbara, Suhny , Prakash, Siddharth K. , Popescu, Bogdan A. , Borger, Michael A. , Milewicz, Dianna M. , Sanders, Stephen Pruett , Song, Jae‐Kwan , Blanke, Philipp , White, Charles S , Siu, Samuel , Enriquez‐Sarano, Maurice , Bax, Jeroen J. , Otto, Catherine M , Schäfers, Hans‐Joachim

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | January 23, 2021 | Volume: 60 | Issue: 3 | Pages: 481-496

10.1093/ejcts/ezab039 | PMID 34292332 Get It

Abstract This International evidence-based nomenclature and classification consensus on the congenital bicuspid aortic valve and its aortopathy recognizes 3 types of bicuspid aortic valve: 1. Fused type, with 3 phenotypes: right-left cusp fusion, right-non cusp fusion and left-non cusp fusion; 2. 2-sinus type with 2 phenotypes: Latero-lateral and antero-posterior; and 3. Partial-fusion or forme fruste. This consensus recognizes 3 bicuspid-aortopathy types: 1. Ascending phenotype; root phenotype; and 3. extended phenotypes.
Impact of KRAS alterations in localized pancreatic cancer (PC).
Shreenivas, Aditya , Annunzio, Kaitlin , Kamgar, Mandana , Chakrabarti, Sakti , Thomas, James P. , Madhavan, Srivats, Dua, Kulwinder S. , Hall, William A. , Christians, Kathleen K. , Evans, Douglas B. , George, Ben , Chakrabarti, Sakti , Khan, Abdul H. , Erickson, Bradley A. , Clarke, Callisia N. , Tsai, Susan , Szabó, Anikó , Urrutia, Raúl , Zimmermann, Michael T. , Reddi, Honey V.

Mayo Clinic

Journal of Clinical Oncology | January 22, 2021 | Volume: 39 | Issue: 3_suppl | Pages: 431-431

10.1200/jco.2021.39.3_suppl.431 Get It

431 Background: Patients (pts) with localized PC do not routinely undergo comprehensive genomic profiling (CGP) unless they develop recurrent or metastatic disease. KRAS is the most frequently mutated gene in PC, however, the impact of different KRAS mutations in localized PC has not been well characterized. We interrogated our genomic database to analyze the KRAS status in PC pts who presented with localized disease at diagnosis (Dx). Methods: We identified PC pts at our institution who underwent CGP utilizing the Foundation One CDx assay and had localized disease at initial Dx; these pts were categorized into resectable/borderline resectable PC (LPC) and locally advanced PC (LAPC). All pts with LPC and LAPC underwent neoadjuvant chemotherapy and chemoradiation prior to possible surgery (all intended therapy - AIT). Tissue from metastatic sites was used for CGP in pts who developed recurrent/metastatic disease before or after completion of AIT. The primary tumor was used for CGP in pts who completed AIT without subsequent relapse or in the absence of adequate metastatic tissue. Effect of each gene on response and survival outcomes was estimated using proportional odds and Cox regression analysis, respectively, adjusting for stage. Results: 75 pts were identified, median age at Dx was 65 years, 59% were male, 65% had a primary tumor in the pancreatic head. 38 (86%) pts with LPC completed AIT compared to 21 (68%) pts with LAPC (p<0.001). KRAS mutation was detected in 95% (71/75) of pts– 94% (67/71) in codon 12 and 6% (4/71) in codon 61. The various KRAS mutations and their association with completion of AIT is summarized in the table. The likelihood of completing AIT did not differ based on KRAS wildtype (WT) vs mutated status (p =1.00), the mutated codon (codon 12 vs. codon 61; p =1.00) or the individual KRAS point mutations (p = 0.7); however, all patients with G12A (N= 1), G12C (N=1), G12L (N=1) and G12R (N=11) mutations completed AIT. KRAS status (mutated vs. WT) and the individual KRAS mutations were not associated with overall survival (OS) after adjusting for stage (p= 0.13 and p = 0.26 respectively). Median OS for patients with LPC and LAPC, was 39 months (mos) and 29 mos respectively. Conclusions: KRAS status and individual KRAS mutations did not have an impact on completing AIT or mOS; however, these findings need to be interpreted with caution due to the inherent biases involved in such analyses. The clinical significance and functional relevance of KRAS G12A, G12C, G12L and G12R mutations, though relatively rare, needs further characterization as well as mechanistic elucidation. [Table: see text]
Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.
Geyer, Susan M. , Mahoney, Michelle R., Asmis, Timothy R., Knopp, Michael V. , Kumthekar, Priya , Schwartz, Lawrence H., Bergsland, Emily K. , Hall, Nathan C. , Karovic, Sanja , Nixon, Andrew B. , O’Reilly, Eileen M. , Strosberg, Jonathan , Meyerhardt, Jeffrey A. , Maitland, Michael L.

Mayo Clinic

Journal of Clinical Oncology | January 22, 2021 | Volume: 39 | Issue: 3_suppl | Pages: 361-361

10.1200/jco.2021.39.3_suppl.361 Get It

361 Background: Assessment of tumor response in extrapancreatic NETs with metastases can be very challenging. Previous studies suggest a high degree of discordance between local and central imaging reviews, which has implications for clinical practice and trial design. Methods: Serial images archived from a randomized phase II trial (A021202) of pazopanib vs placebo in progressive non-pancreatic NETs were evaluated by central review, with real-time review conducted at the time of locally interpreted progressive disease (PD). The primary endpoint of the trial was progression-free survival (PFS) by central review. Discordances between central (Alliance Imaging Core Laboratory) and local (investigator-reported) reviews were assessed. Scan-level and pt-level results across both treatment arms were evaluated. Kappa tests were used to test concordance based on source of review. Results: 151 pts had a total of 724 scans with response adjudication by both local and central RECIST review. Discordance was observed in both directions. Overall, 20% of scans (143/724) had discordant classifications. The most common discordances were: stable disease (SD) on local vs. PD on central review (82/143=57%), and PD on local vs. SD on central review (32/143=22%). On a pt level, 78 of 151 pts (52%) had discordant reviews; 8 had >1 type of discordance. Overall, 30% of pts (N=45) had a determination of PD on central review, but SD or better on local review, potentially resulting in excessive exposure to therapy. In contrast, 20% (N=30) were classified as PD on local read but SD or better on real-time central review (which did not necessarily translate into an abbreviated course of treatment). Cohen’s kappa statistics revealed only moderate concordance between local and central reviewers both at the scan (K=0.48, 95% CI: 0.42 – 0.55) and pt (K=0.41, 95% CI: 0.32 – 0.5) levels, with no significant influence by treatment arm, primary tumor site, tumor functionality, histology, differentiation or primary disease spread. Conclusions: Discordance was observed in both directions, where 30% of pts were potentially kept on study drug too long (based on central read), and 20% would have been taken off study treatment early for local PD were it not for real-time central review. Although this bidirectional discordance did not affect the overall findings of the PFS outcome between arms in the trial, these analyses highlight the high prevalence of discordance, the potential to negatively influence treatment duration in both directions, and the need for more straightforward methods of assessing treatment response in carcinoid. Support: U10CA180821, U10CA180882, U24CA196171; NETRF Investigator Award; https://acknowledgments.alliancefound.org Clinical trial information: NCT01841736.
Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance).
Geyer, Susan M. , Innocenti, Federico , Luk, Lyndon , Wen, Yujia , Zhao, Binsheng , Schwartz, Lawrence H., Dercle, Laurent , Nixon, Andrew B. , Shi, Qian , Jacobson, Sawyer , Liu, Andy , Yang, Hao , Bertagnolli, Monica M. , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M. , Venook, Alan P. , Abou‐Alfa, Ghassan K.

Mayo Clinic

Journal of Clinical Oncology | January 22, 2021 | Volume: 39 | Issue: 3_suppl | Pages: 343-343

10.1200/jco.2021.39.3_suppl.343 Get It

343 Background: Alliance/CALGB 80802, a randomized phase III trial, evaluated sorafenib plus doxorubicin vs. doxorubicin in pts with HCC and showed no improvement in median overall survival (OS) (HR[95CI] 1.05[0.83-1.31]) or PFS (HR[95CI] 0.93[0.75-1.16]). In HCC surrogacy of tumor response with OS remains controversial, in part due to varying criteria used for response evaluation (e.g., RECIST1.1 and mRECIST). We evaluated the performance of several models to predict OS using pretreatment clinical and radiomic variables. Methods: In CALBG 80802, we segmented all measurable tumor lesions on sequential CT scans. A lesion’s imaging phenotype was deciphered with 23 uncorrelated quantitative imaging features measured at baseline and week (wk) 10 (first follow-up). An OS landmark survival analysis was conducted at wk 10. Patients were randomly assigned (3:1) to training (n = 92) and validation (n = 37) sets. In a training set, 6 random forest predictive models (6 signatures) used features that best predicted OS using 3 sets of variables: radiomics only (n = 23), clinical only (n = 9), radiomics and clinical (n = 32). Two time points (baseline only or baseline + wk 10) were assessed. Each signature's output was an individualized prediction and a continuous value ranging from 0 to 1 (from most to least favorable predicted OS). The primary endpoint was to compare these models' performance to predict OS using error rate (Harrell's concordance-index) in the validation set. Results: Of the 6 training signatures evaluated, the one achieving the highest performance in the validation set was an 8-feature signature combining radiomics and clinical variables measured at two time points (baseline + wk 10) with an error rate of 35.6%. The variables [rank of importance] (table) selected by the signature included baseline clinical features (albumin[1], AFP[2], Child-Pugh[4]), baseline radiomics features (component 17[3], component 1[5], component 9[7], tumor volume[8]) and wk 10 radiomics features (delta tumor volume[6]). Variable delta tumor volume [6] used a more enhanced estimation of tumor burden at baseline and a delta tumor volumetric measurement; compared to RECIST1.1 measurement of percentage change in unidimensional measurement of a subset of target lesions. The four quartiles of the signature were significantly associated with OS (Log-Rank, P < 0.0001). Conclusions: The selected combined radiomic and clinical composite signature provided the best prediction for OS in the 80802 study patients’ population. It is a suggested way forward to go beyond single anatomic measurement techniques such as RECIST or mRECIST. [Table: see text]
Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).
Dika, Imane H. El, Geyer, Susan M. , Innocenti, Federico , Yaqubie, Amin , Lopez, Juan C., Huang, Binhui , Wen, Yujia , Schwartz, Lawrence H., Nixon, Andrew B. , Shi, Qian , Jacobson, Sawyer , Tang, Yi‐Wei , Bertagnolli, Monica M. , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M. , Venook, Alan P. , Abou‐Alfa, Ghassan K.

Mayo Clinic

Journal of Clinical Oncology | January 22, 2021 | Volume: 39 | Issue: 3_suppl | Pages: 325-325

10.1200/jco.2021.39.3_suppl.325 Get It

325 Background: Alliance/CALGB 80802 randomized phase III trial evaluated DO+S vs. S in pts with aHCC, and showed no improvement in median OS. Multi-drug resistant pathway mitigation by the Ras/Raf/MEK/ERK pathway and bFGF-mediated activation of Raf-1 promotes the formation of antiapoptotic Raf-1 and ASK1 complex, induced by anthracyclines. S efficiently blocks NS5A-recruited c-Raf mediated HCV replication and viral gene expression. Once inhibited by S, VEGF expression of HepG2 may limit HCV cellular entry. Release of Raf-1-Ask-1 dimer and inhibition of Raf-1 via S putatively differ in the presence or absence of DO. We hypothesize treatment with S reduces HCV titer levels (TL) and influence pts’ outcome. Methods: In 80802 HCV pts, TL were evaluated in both arms at baseline and post-baseline at Day 1 of Cycles 2, 3, and every 2 cycles and at progression or discontinuation of therapy. HCV undetectable (HCV-UN) levels were defined as < 50 copies/mL. TL were evaluated in relation to OS and PFS. HCV RNA levels were measured by TaqMan PCR and by genotype. Results: Of 356 pts, 83 were HCV+ with more Black/African American (25/50 = 50%) vs. White (54/239 = 23%) or other race groups (4/67 = 6%) (p < 0.0001). HCV titer data were available on 54 pts (S: 28, DO+S: 26). At baseline, 12 pts (S: 7, DO+S: 5) were HCV-UN, and post-baseline HCV TL did not significantly differ between treatment arms; one patient in each arm went from detectable (HCV-D) to HCV-UN. Post-baseline, 40 pts were HCV-D vs. 14 who were HCV-UN (S+DO: 8, S: 6 pts). Except for the two pts who became HCV-UN, baseline HCV-D vs. HCV-UN titers was similar to that status post-baseline. PFS and OS between HCV-D and HCV-UN both at baseline and post-baseline are delineated in the table. Conclusions: We observed that S did not influence HCV TL. Pts treated with DO+S vs. S had worse PFS if they had HCV-UN, and further that higher levels of HCV titers at baseline were associated with significantly improved PFS. Given the small sample size, these findings warrant further prospective evaluation. Support: U10CA180821, U10CA180882, U24CA196171; Bayer, Bristol-Myers-Squibb, and Sanofi. https://acknowledgments.alliancefound.org . Clinical trial information: NCT01015833. [Table: see text]
The Society for the Advancement of Transplant Anesthesia (SATA) enters a new partnership with Clinical Transplantation
Mandell, M. Susan , Sakai, Tetsuro , Wagener, Gebhard , Marchi, Lorenzo De , Subramaniam, Kathirvel , JHuang, Jiapeng, Hendrickse, Adrian , Ryan, Chadha, Deshpande, Ranjit , Deshpande, Ranjit , Pretto, Ernesto A.

Mayo Clinic

Clinical Transplantation | January 21, 2021 | Volume: 35 | Issue: 2 | Pages: No page available

10.1111/ctr.14203 | PMID 33475197 Get It

Differences in calculated percentage improvement versus patient-reported percentage improvement in pain scores: a review of spinal cord stimulation trials
Hagedorn, Jonathan M. , Deer, Timothy R. , Canzanello, Nicholas , Covington, Stephen , Schroeder, Darrell R. , Bendel, Markus A. , Moeschler, Susan M. , Hooten, W. Michael , Canzanello, Nicholas C, Covington, Stephen M, Hagedorn, Jonathan M , Deer, Tim , Schroeder, Darrell

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 21, 2021 | Volume: 46 | Issue: 4 | Pages: 293-297

10.1136/rapm-2020-102238 | PMID 33479116 Get It

Introduction Spinal cord stimulation is frequently used for the treatment of intractable chronic pain conditions. Trialing of the spinal cord stimulator device is recommended to assess the patient’s response to neurostimulation before permanent implantation. The trial response is often assessed by Numeric Rating Scale changes and patient-reported percentage pain improvement. Using number rating scale changes between prespinal and postspinal cord stimulation trial, a calculated percentage pain improvement can be obtained. The aim of this study was to assess the difference between calculated and patient-reported percentage improvement in pain scale during spinal cord stimulation trials. Methods This study was a retrospective single center review of all spinal cord stimulation trials from January 1 2017 to July 1 2019. A total of 174 patients were included. The paired t-test was used to compare numeric pain scores obtained prestimulation versus poststimulation. The mean difference between methods (patient-reported minus calculated) was compared with zero using the 1-sample t-test. Lin’s concordance correlation coefficient was computed with a 95% CI, calculated using Fisher z-transformation; and a bootstrapping approach was used to compare the concordance correlation coefficient between groups. In all cases, two-tailed tests were used with p<0.05 considered statistically significant. Results Based on prestimulation and poststimulation numeric rating scale scores, the mean±SD calculated percentage improvement in pain scale was 54±28. The mean±SD patient-reported percentage improvement in pain scale was 59±25. The overall 95% limits of agreement for the two methods are −30% to +41%. The overall concordance correlation coefficient was 0.76 (95% CI 0.69 to 0.81). Conclusion Although the two methods are highly correlated, there is substantial lack of agreement between patient-reported and calculated percentage improvement in pain scale, suggesting that these measures should not be used interchangeably for spinal cord stimulator trial outcome assessment. This emphasizes the need for improved metrics to better measure patient response to neuromodulation therapies. Additionally, patient-reported percentage improvement in pain was found to be higher than calculated percentage improvement in pain, potentially highlighting the multidimensional experience of pain and the unpredictability of solely using Numeric Rating Scale scores to assess patient outcomes.
A Population-Based Study of Genes Previously Implicated in Breast Cancer
Hart, Steven N. , Huang, Hongyan , Gao, Chi , Lilyquist, Jenna , Yadav, Siddhartha , Samara, Raed, Klebba, Josh, Auer, Paul L. , Carter, Brian D., Eliassen, Heather, Gapstur, Susan M. , Gaudet, Mia M. , Haiman, Christopher A. , Hodge, James M. , Jacobs, Eric J. , John, Esther M. , Kurian, Allison W. , Lindströem, Sara, Lindstrom, Tricia, Ma, Huiyan , Ong, Irene M. , Patel, Alpa V. , Reid, Sonya , Taylor, Jack A. , Vachon, Celine M. , Weitzel, Jeffrey N. , Goldgar, David E. , Nathanson, Katherine L. , Chen, Chen , Hart, Steven N , Gnanaolivu, Rohan , Na, Jie , Boddicker, Nicholas J, Ambrosone, Christine B. , Bernstein, Leslie , Burnside, Elizabeth S. , Gaudet, Mia, Le Marchand, Loic, Neuhausen, Susan, O'Brien, Katie M, Rosenberg, Lynn, Tamimi, Rulla, Trentham-Dietz, Amy, Weinberg, Clarice, Polley, Eric C. , Couch, Fergus J. , Weitzel, Jeffrey N , John, Esther M , Yadav, Siddhartha , Ong, Irene M , Taylor, Jack A , Nathanson, Katherine L , Hodge, James M , Kurian, Allison W , Hu, Chunling , Lee, Kun Y. , Boddicker, Nicholas , Anton‐Culver, Hoda , Bandera, Elisa V. , Bertrand, Kimberly A. , Eliassen, A. Heather , Hunter, David J. , Kooperberg, Charles , Marchand, Loı̈c Le , Neuhausen, Susan L. , Newcomb, Polly A. , O’Brien, Katie M. , Olson, Janet E. , Pal, Tuya , Palmer, Julie R. , Rosenberg, Lynn A. , Sandler, Dale P. , Scott, Christopher, Tamimi, Rulla M. , Trentham‐Dietz, Amy , Vachon, Celine M. , Weinberg, Clarice R. , Yao, Song , Ziogas, Argyrios , Domchek, Susan M. , Kraft, Peter , Couch, Fergus J.

Mayo Clinic

New England Journal of Medicine | January 20, 2021 | Volume: 384 | Issue: 5 | Pages: 440-451

10.1056/nejmoa2005936 | PMID 33471974 Get It

Interlaboratory Agreement of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Serologic Assays in the Expedited College of American Pathologists Proficiency Testing Program
Tacker, Danyel H. , Bashleben, Christine , Long, Thomas C., Theel, Elitza S. , Knight, Vijaya , Kadkhoda, Kamran , Rhoads, Daniel D. , Fink, Susan L. , Rhoads, Daniel D , Linden, Michael A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 18, 2021 | Volume: 145 | Issue: 5 | Pages: 536-542

10.5858/arpa.2020-0811-sa | PMID 33461214 Get It

Context.— Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged, currently pandemic virus, and the etiologic agent of coronavirus disease 2019 (COVID-19). Clinical testing for antibodies to SARS-CoV-2 has rapidly become widespread, but data regarding the interlaboratory performance of these serologic assays are limited. Objective.— To describe the development and initial results of the College of American Pathologists (CAP) SARS-CoV-2 Serology Survey. Design.— Members from the CAP Microbiology and Diagnostic Immunology and Flow Cytometry Committees formed a working group to support development of a new proficiency testing survey for anti–SARS-CoV-2 antibody assays. Supplemental questions in the survey assessed the state of SARS-CoV-2 serologic testing among participating laboratories as of July 2020. Results were analyzed for agreement by immunoglobulin (Ig) isotype tested, assay manufacturer, and methodology. Results.— A total of 4125 qualitative results were received from 1110 laboratories participating in the first survey. Qualitative agreement for assays measuring anti–SARS-CoV-2 total antibodies or IgG was greater than 90% for all 3 samples in the survey. Qualitative agreement for IgM and IgA for the negative sample was greater than 95%, but lacked consensus for the other 2 samples. Conclusions.— These initial data suggest overall excellent agreement and comparable performance for most qualitative anti–SARS-CoV-2 IgG and total antibody assays across all participating clinical laboratories, regardless of specific target antigen or assay methodology.